Takeda Pharmaceutical Company Limited American Depositary Shares (each
TAK Real Time Price USDRecent trades of TAK by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in TAK holdings by institutional investors
Quarterly net insider trading by TAK's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,450,000 Oct 20, 2026 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$610,000 Jul 20, 2026 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Trade (domestic/foreign) Defense
-
$1,410,000 Apr 20, 2026 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$590,000 Jan 20, 2026 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$1,370,000 Oct 20, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$1,570,000 Aug 26, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$490,000 Apr 22, 2025 Issue: Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Defense Medicare/Medicaid Health Issues
-
$390,000 Apr 18, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$970,000 Oct 18, 2024 Issue: Budget/Appropriations Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$1,050,000 Jul 22, 2024 Issue: Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$510,000 Jan 19, 2024 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$1,380,000 Oct 20, 2023 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
Former government officials who have lobbied for TAK
TAK Estimated quarterly lobbying spending
TAK Revenue by Segment or Geography
New TAK patent grants
-
Patent Title: Heterocyclic compound Dec. 05, 2017
-
Patent Title: Cyclic compounds Nov. 28, 2017
-
Patent Title: Fumagillol derivatives Nov. 28, 2017
-
Patent Title: Production method for poly(amino acid) Nov. 14, 2017
-
Patent Title: Process for producing heterocyclic compound Nov. 07, 2017
-
Patent Title: Pyridinyl and fused pyridinyl triazolone derivatives Oct. 31, 2017
-
Patent Title: Anti-cd38 antibodies Oct. 17, 2017
-
Patent Title: Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists Oct. 17, 2017
-
Patent Title: Piperidine and azepine derivatives as prokineticin receptor modulators Oct. 17, 2017
-
Patent Title: Nitrogen-containing heterocyclic compound Oct. 17, 2017
-
Patent Title: Nitrogen-containing heterocyclic compound Oct. 17, 2017
-
Patent Title: Bicyclic heterocyclic compound containing a substituted pyrrole ring Oct. 03, 2017
-
Patent Title: Aromatic compounds with gpr40 agonistic activity Oct. 03, 2017
-
Patent Title: Nitrogen-containing heterocyclic compound Oct. 03, 2017
-
Patent Title: Quinoxaline derivatives as gpr6 modulators Sep. 26, 2017
-
Patent Title: 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 Sep. 26, 2017
-
Patent Title: Production method of thienopyrimidine derivative Sep. 12, 2017
-
Patent Title: Solid preparation Sep. 12, 2017
-
Patent Title: Cyclopropanamine compound and use thereof Sep. 05, 2017
-
Patent Title: Tetrahydronaphthyridine somatostatin receptor 5 antagonists Sep. 05, 2017
-
Patent Title: Pyridazinones as daao enzyme inhibitors Sep. 05, 2017
-
Patent Title: Fused heterocyclic compound Aug. 29, 2017
-
Patent Title: Bicyclic heterocyclic compound containing a substituted pyrrole ring Aug. 15, 2017
-
Patent Title: Modified nucleic acid Aug. 08, 2017
-
Patent Title: Cyclopropanamine compound and use thereof Aug. 01, 2017
-
Patent Title: Cyclopropanamine compound and use thereof Jul. 25, 2017
-
Patent Title: Sustained-release composition and method for producing the same Jul. 25, 2017
-
Patent Title: Substituted pyrido[3,4-b]pyrazines as gpr6 modulators Jul. 18, 2017
-
Patent Title: 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide inhibitors of phd Jul. 18, 2017
-
Patent Title: 5-ht3 receptor antagonists Jul. 04, 2017
-
Patent Title: Dry-coated tablet Jul. 04, 2017
-
Patent Title: Cyclopropaneamine compound Jun. 20, 2017
-
Patent Title: Conjugated anti-cd38 antibodies Jun. 13, 2017
-
Patent Title: Nitrogen-containing heterocyclic compound Jun. 13, 2017
-
Patent Title: 5-ht3 receptor antagonists Jun. 06, 2017
-
Patent Title: Substituted 6-aza-isoindolin-1-one derivatives May. 30, 2017
-
Patent Title: Nitrogen-containing heterocyclic compound May. 30, 2017
-
Patent Title: Heterocyclic compound May. 23, 2017
-
Patent Title: Nitrogen-containing heterocyclic compound May. 23, 2017
-
Patent Title: Heterocyclic compound May. 16, 2017
-
Patent Title: Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors May. 09, 2017
-
Patent Title: Heterocyclic compounds having cholesterol 24-hydroxylase activity May. 09, 2017
-
Patent Title: Heterocyclic compound May. 02, 2017
-
Patent Title: Heterocyclic compound Apr. 25, 2017
-
Patent Title: Heterocyclic compound Apr. 18, 2017
-
Patent Title: 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors Apr. 18, 2017
-
Patent Title: Sustained-release composition and method for producing the same Apr. 11, 2017
-
Patent Title: Cyclic compounds Apr. 04, 2017
-
Patent Title: Spiro azetidine isoxazole derivatives and their use as sstr antagonists Mar. 28, 2017
-
Patent Title: Heteroarylamide inhibitors of tbk1 Mar. 21, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to TAK from public contracts
Recent insights relating to TAK
Recent picks made for TAK stock on CNBC
ETFs with the largest estimated holdings in TAK
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $TAK stock a Buy, Sell, or Hold?
- What is the price target for $TAK stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $TAK stock?
- Who owns the most shares of $TAK stock?
- What funds own $TAK stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TAK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Takeda Pharmaceutical Company Limited American Depositary Shares (each (TAK) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Takeda Pharmaceutical Company Limited American Depositary Shares (each (TAK).
Quiver Premium charts TAK's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at TAK, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|